Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

BH3 mimetics like venetoclax target prosurvival Bcl-2 family proteins and are important therapeutics in the treatment of hematological malignancies. We demonstrate that endogenous Bfl-1 expression can render preclinical lymphoma tumor models insensitive to Mcl-1 and Bcl-2 inhibitors. However, suppre...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Boiko, Scott, Proia, Theresa, San Martin, Maryann, Gregory, Gareth P., Wu, Michelle Min, Aryal, Neeraj, Hattersley, Maureen, Shao, Wenlin, Saeh, Jamal C., Fawell, Stephen E., Johnstone, Ricky W., Drew, Lisa, Cidado, Justin
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2021
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8160501/
https://ncbi.nlm.nih.gov/pubmed/33259592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020008528
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires